Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acids and salts thereof
Reexamination Certificate
2002-11-19
2011-11-22
Sullivan, Daniel (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acids and salts thereof
C562S460000, C562S459000, C514S557000, C514S553000, C514S576000
Reexamination Certificate
active
08063242
ABSTRACT:
(R) and (S) 2-Aryl-propionic acids, and pharmaceutical compositions that contain them, are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The acids are used for the prevention and treatment of pathologies deriving from said activation. In particular, the (R) enantiomers of said acids are lacking cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
REFERENCES:
patent: 3629320 (1971-12-01), Wasley
patent: 3766263 (1973-10-01), Godfrey
patent: 4465855 (1984-08-01), Palosi et al.
patent: 4720506 (1988-01-01), Munakata et al.
patent: 5981592 (1999-11-01), Wechter et al.
patent: 621 255 (1963-02-01), None
patent: 2362888 (2000-08-01), None
patent: 25 33 397 (1976-02-01), None
patent: 94599 (1983-11-01), None
patent: 0 935 961 (1999-08-01), None
patent: 415 446 (1976-02-01), None
patent: 0006184 (2000-02-01), None
patent: 1 132 318 (1968-10-01), None
patent: 1 465 661 (1977-02-01), None
patent: 1521906 (1978-08-01), None
patent: 53007640 (1978-01-01), None
patent: 98 09603 (1998-03-01), None
patent: 00 06184 (2000-02-01), None
patent: 01 58852 (2001-08-01), None
Haringman et al. Arthritis Res. Ther. 2004, 6, 93-97.
Brancaccio et al J Med. Chem. 1981, 24, 998-1000.
Derwent WPI, Section Ch. Week 197735, Derwent Publications Ltd., London, GB; AN 1977-61579Y, XP002236684 & JP 52 083822A (Jul. 13, 1977).
Brancaccio et al., J. Med. Chem., vol. 24, pp. 998-1000 (1981).
Atkinson et al., J. Med. Chem., vol. 26, pp. 1353-1360 (1983).
Rufer et al., European Journal of Medicinal Chemistry, Editions Scientifique Elsevier, Paris, FR., vol. 13, No. 2, pp. 193-198 (Mar. 1978).
Yorizumi, K., et al., “An Autopsy Case of Malignant Melanoma, Misdiagnosed as Pulmonary Cancer: Effect of Naproxen on Tumor Fever on Malignant Melanoma,” IRYO, vol. 42, No. 4, pp. 357-362 (1988).
Kamper, A. L., et al., “Effects of Sulindac and Naproxen in Patients with Chronic Glomerular Disease,” Scand. J. Rheumatology, pp. 26-31 (1986).
Burdick, K. H., et al., “Naproxen and Psoriasis,” Arch. of Derma., vol. 112, No. 1, p. 121 (1976).
Jiang, W., et al., “Differential Effects of Naproxen on Ischemia and Reperfusion-Induced Excitation of Jejunal Afferents in the Anarsthetised Rat,” Gastroenterology, vol. 114, No. 4, G3183 (1988).
Allegretti Marcello
Bertini Riccardo
Bizzarri Cinzia
Cesta Maria Candida
Colotta Francesco
Birch & Stewart Kolasch & Birch, LLP
Dompe PHA.R.MA S.p.A.
Sullivan Daniel
Valenrod Yevegeny
LandOfFree
2-aryl-propionic acids and pharmaceutical compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-aryl-propionic acids and pharmaceutical compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-aryl-propionic acids and pharmaceutical compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4280284